| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 5 | -42.9K | 100% | $2.60 | -$111K |
| Net | -5 | -42.9K | -100% | -$111K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Michael J. Sofia | Chief Scientific Officer | $3.82M | -$23.1K | -0.6% | Feb 1, 2024 |
| Michael J. McElhaugh | Interim President & CEO, Director | $3.48M | -$23.5K | -0.67% | Feb 1, 2024 |
| William H. Collier | President and CEO, Director | $1.1M | Feb 1, 2023 | ||
| Elizabeth Howard | EVP, GC, Compliance | $438K | Feb 1, 2023 | ||
| David C. Hastings | Chief Financial Officer | $421K | -$22.2K | -5.01% | Feb 1, 2024 |
| Karen Sims | Chief Medical Officer | $290K | -$10.1K | -3.35% | Feb 1, 2024 |
| J. Christopher Naftzger | General Counsel and CCO | $220K | Feb 1, 2024 | ||
| Keith Manchester | Director | $170K | -$32.6K | -16.1% | Aug 14, 2024 |
| Richard C. Henriques Jr | Director | May 23, 2024 | |||
| Melissa Rewolinski | Director | May 23, 2024 | |||
| James R. Meyers | Director | May 23, 2024 | |||
| Daniel D. Burgess | Director | May 23, 2024 | |||
| Roivant Sciences Ltd. | 10%+ Owner | Oct 18, 2021 | |||
| Andrew Cheng | Director | Jun 3, 2021 | |||
| Frank Torti | Director | May 23, 2024 | |||
| Tram Tran | Director | May 25, 2022 | |||
| Gaston Picchio | Chief Development Officer | Jan 20, 2022 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|